SCHEMBL4316869

SCHEMBL4316869

COC(=O)[C@@H]1CC(N2CCCC(C)(C)C2)CN1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.40
CDK9 P50750 1/20 0.40
AGTR2 P50052 1/20 0.37
NR1H2 P55055 1/20 0.36
NR1H3 Q13133 1/20 0.36
CCR2 P41597 4/20 0.36
P2RX3 P56373 2/20 0.34
ALDH1A1 P00352 1/20 0.34
PTPN1 P18031 1/20 0.34
MMP2 P08253 1/20 0.33
ANPEP P15144 1/20 0.33
HSD17B10 Q99714 1/20 0.33
POLB P06746 2/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD11B1 P28845 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NPC1 O15118 1/20 0.32
EPHX2 P34913 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4316868 1.00 CCNT1 (0.40) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL4315222 0.88 HSD17B10 (0.39) AGTR2CCR2P2RX3HSD17B10HSD11B1
SCHEMBL29524293 0.87 CCNT1 (0.41) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL6536648 0.87 CCNT1 (0.41) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL4309204 0.86 CCNT1 (0.41) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL29889444 0.86 CCNT1 (0.41) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL4309208 0.86 CCNT1 (0.41) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL21950735 0.81 CCNT1 (0.41) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL14915300 0.79 USP2 (0.44) CCNT1CDK9AGTR2NR1H2NR1H3
SCHEMBL15397259 0.79 USP2 (0.44) CCNT1CDK9AGTR2NR1H2NR1H3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090069376-A1 VLA-4 Antagonists MERCK SHARP & DOHME CORP. 2009-03-12 US disclosed
EP-1874299-A2 VLA-4 ANTAGONISTS Merck & Co., Inc. (US) 2008-01-09 EP disclosed
WO-2006115918-A2 VLA-4 ANTAGONISTS MERCK & CO., INC. (US) 2006-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069376-A1 VLA-4 Antagonists VCAM1, SELPLG, ITGB4 CCNT1 3334/4885CDK9 2231/4885AGTR2 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.